Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.72 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.72 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.72 |
| ▸ | GJB2 | P29033 | 1/20 | 0.53 |
| ▸ | IGF2R | P11717 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.48 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21813016 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4GJB2IGF2R | |
| SCHEMBL8773138 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4GJB2IGF2R | |
| SCHEMBL8773131 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4GJB2IGF2R | |
| SCHEMBL18947588 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4GJB2IGF2R | |
| SCHEMBL17987617 | 1.00 | LGALS3 (0.72) | LGALS3LGALS8LGALS4GJB2IGF2R | |
| SCHEMBL23393558 | 0.96 | LGALS3 (0.74) | LGALS3LGALS8LGALS4GJB2IGF2R | |
| SCHEMBL18947589 | 0.96 | LGALS3 (0.74) | LGALS3LGALS8LGALS4GJB2IGF2R | |
| SCHEMBL25005884 | 0.95 | LGALS8 (0.77) | LGALS3LGALS8LGALS4GJB2MAPK1 | |
| SCHEMBL22067763 | 0.95 | LGALS8 (0.77) | LGALS3LGALS8LGALS4GJB2MAPK1 | |
| SCHEMBL23183598 | 0.95 | LGALS8 (0.77) | LGALS3LGALS8LGALS4GJB2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | LGALS3 347/4885LGALS8 437/4885LGALS4 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.